Edit |   |
---|---|
Antigenic Specificity | TNFSF10 |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human |
Isotype | n/a |
Format | affinity purified |
Size | 0.1 mL |
Concentration | n/a |
Applications | Western Blot (WB), Immunohistochemistry (IHC) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1, 2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-kappaB activation (7, 9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In additi |
Immunogen | Immunogen: A synthetic peptide of human TNFSF10 Storage Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
Other Names | [APO2L; Apo-2L; CD253; TL2; TRAIL] |
Gene, Accession # | [TNFSF10], Gene ID: 8743, NCBI: NP_001177871.1, UniProt: P50591 |
Catalog # | MBS8505410 |
Price | $310 |
Order / More Info | TNFSF10 Antibody from MYBIOSOURCE INC. |
Product Specific References | 1. Wiley, S.R. et al. (1995) Immunity 3, 673-82. 2. Pitti, R.M. et al. (1996) J Biol Chem 271, 12687-90. 3. Almasan, A. and Ashkenazi, A. Cytokine Growth Factor Rev 14, 337-48. 4. Pan, G. et al. (1997) Science 276, 111-3. 5. Walczak, H. et al. (1997) EMBO J 16, 5386-97. 6. MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20. 7. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30. 8. Schneider, P. et al. (1997) FEBS Lett 416, 329-34. 9. Shetty, S. et al. (2002) Apoptosis 7, 413-20. 10. Sheridan, J.P. et al. (1997) Science 277, 818-21. 11. Degli-Esposti, M.A. et al. (1997) J Exp Med 186, 1165-70. 12. MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20. 13. Schneider, P. et al. (1997) FEBS Lett 416, 329-34. 14. Pan, G. et al. (1998) FEBS Lett 424, 41-5. 15. Marsters, S.A. et al. (1997) Curr Biol 7, 1003-6. 16. Kelley, S.K. et al. (2001) J Pharmacol Exp Ther 299, 31-8. 17. Walczak, H. et al. (1999) Nat Med 5, 157-63. 18. Ashkenazi, A. et al. (1999) J Clin Invest 104, 155-62. |